Clinical trials: FLU
Influenza, Human
Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy
This research aims to identify which behavioral science strategies are most effective at increasing flu vaccination rates overall and based on patients' individual characteristics.
- Trial name
- NCT04590066
- Testing
- Flu shot text messages
- Where
- United States
- Volunteers
- 734,383 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Influenza, Flu
Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years
This was a blind-observer, monocenter, randomized, comparative, Phase IV study designed to evaluate the immunogenicity and safety of the Sanofi Pasteur Shenzhen Trivalent Influenza Vaccine (SP Shz TIV) versus the Trivalent…
- Trial name
- NCT03344029
- Testing
- SP Shz TIV, Hualan TIV
- Where
- China
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Sanofi
Human Influenza
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
To evaluate the safety of a single intramuscular (IM) injection of trivalent nonadjuvated influenza study vaccine, formulation 2012/2013, in adult and elderly subjects and the antibody response to each influenza vaccine antigen…
- Trial name
- NCT01636102
- Testing
- Trivalent influenza virus vaccine (TIV)
- Where
- Belgium
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
COVID-19
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine.
- Trial name
- NCT06291857
- Testing
- CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine
- Where
- 58 sites in Australia, New Zealand
- Volunteers
- 9,320 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza Vaccine
A Phase 2 Study to Evaluate Immune Responses of FluMist®
The primary objective of this study is to describe the level of serum antibody and cellular immune responses conferred by FluMist and TIV against influenza virus strains.
- Trial name
- NCT00461981
- Testing
- TIV, Trivalent Inactivated Influenza Virus Vaccine, FluMist, Influenza Virus Vaccine Live
- Where
- 19 sites in United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Fever, Wheezing
Fever and Wheezing Events in Children After US Influenza Vaccines Using Text Messaging
Children 2-11 years of age who are given the influenza vaccine (inactivated influenza (IIV) or live attenuated influenza vaccine (LAIV)) as part of their routine care can enroll in this study if their parent has the ability to…
- Trial name
- NCT02295007
- Testing
- text message
- Where
- 3 sites in United States
- Volunteers
- 266 people
- Sponsor
- Columbia University
Acute Upper Respiratory Tract Infection, Influenza
Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers
this study evaluates the use of Kagocel for the prevention of acute respiratory viral infections (ARVI) and influenza during the epidemic rise in morbidity in Russia in the 2017-2018 season (epidemiology: number of cases during…
- Conditions
- Acute Upper Respiratory Tract Infection, Influenza, Respiratory Viral Infection
- Trial name
- NCT04611061
- Testing
- Kagocel, No one
- Where
- Russia
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Nearmedic Plus LLC
Influenza
H5N1 (Clade 2) Vaccination of Adults and Elderly
The purpose of this research study is to study the safety and effectiveness of vaccinating individuals who have previously received an avian influenza vaccine derived from one type of H5N1 virus with a vaccine derived from a…
- Trial name
- NCT00680069
- Testing
- Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
- Where
- 8 sites in United States
- Volunteers
- 517 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Adult Influenza Vaccination Text Message Reminders With Electronic Health Record Alerts
Influenza infection leads to on average 3000-49,0000 deaths and 150,000 hospitalizations annually. While vaccination is the cornerstone of preventing influenza infection, vaccination coverage in adults is low.
- Trial name
- NCT02284594
- Testing
- text message
- Where
- United States
- Volunteers
- 4,026 people
- Sponsor
- Columbia University
Influenza
Eldery High Dose TIV 2005
The purpose of this study is to compare a new higher-dose influenza virus vaccine to the standard dose vaccine in elderly adults who can walk.
- Trial name
- NCT00115531
- Testing
- Trivalent inactivated influenza vaccine
- Where
- 5 sites in United States
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasma Cell Neoplasm
Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
This phase IV trial studies how well influenza vaccination works in preventing infections such as influenza in patients with plasma cell disorders.
- Trial name
- NCT04080531
- Testing
- Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine
- Where
- 2 sites in United States
- Volunteers
- 165 people
- Sponsor
- Emory University
COVID - 19, Influenza A
Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test
This observational study aims to evaluate the diagnostic performance of an investigational Influenza A/B and COVID-19 test in patients presenting with signs and symptoms of respiratory infection.
- Conditions
- COVID - 19, Influenza A, Influenza B
- Trial name
- NCT07190131
- Testing
- Investigational Flu A/B And Covid-19 Diagnostic Test
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 588 people
- Sponsor
- iHealth Labs inc
Respiratory Viral Infections, Influenza
Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections
The goal of this clinical trial is to evaluate the effects of myxovirus resistance protein A (MxA)-guided antiviral treatment on treatment duration and adverse outcomes in adults hospitalized with influenza or COVID-19, compared…
- Conditions
- Respiratory Viral Infections, Influenza, SARS CoV 2 Infection
- Trial name
- NCT07892872
- Testing
- Baseline MxA testing, Serial MxA testing, MxA result feedback and antiviral treatment recommendations
- Where
- China
- Volunteers
- 618 people
- Sponsor
- Capital Medical University
SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)
COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
The most recently discovered coronavirus (SARS-CoV-2) may cause illness in humans ranging from the common cold to serious illness, also referred to as Coronavirus disease 2019 (COVID-19).
- Trial name
- CV-NCOV-011 (NCT04848467)
- Testing
- SARS-CoV-2 mRNA Vaccine (CVnCoV), Quadrivalent influenza vaccine (QIV)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bayer
Influenza
Immunogenicity and Safety of Different Doses of Fluzone® Influenza
The purpose of this research study is to find out if giving the smaller dose of flu vaccine under the skin generates antibodies against flu compared to giving the vaccine the usual way, as a shot in the arm.
- Trial name
- NCT00253734
- Testing
- Fluzone® (IM), Fluzone®
- Where
- United States
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults
This study is designed to test the immunogenicity in terms of Hemagglutination Inhibition (HI) antibodies against each of the three vaccine influenza strains and reactogenicity and safety of Fluviral® containing the influenza…
- Trial name
- NCT01626820
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Virus
Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults
Influenza virus infections are a major cause of morbidity and mortality. The limited existing knowledge about the impact of influenza in immunocompromised patients suggests that they are at increased risk of influenza virus…
- Trial name
- NCT00998803
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- St. Jude Children's Research Hospital
Seasonal Influenza
Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers
The present study will evaluate the safety in healthy people aged 1- 45 years (male and female) after single intramuscular (IM) dose of trivalent subunit inactivated influenza vaccine till the 30-days follow-up period.
- Trial name
- NCT01123954
- Testing
- Seasonal flu vaccine
- Where
- Vietnam
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Use of Probiotics to Prevent Influenza
The goal of this study is to assess the feasibility of randomizing residents of long-term care facilities to either probiotics or placebo to assess whether probiotics can reduce influenza and other viral laboratory confirmed…
- Trial name
- NCT01720329
- Testing
- Probiotics
- Where
- 13 sites in Canada
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- McMaster University
Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom
The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?
The study use UK based linked electronic health records from the Clinical Research Datalink (CALIBER) of 5.6 million individuals to conduct a matched case-control study to investigate the incidence of influenza in individuals…
- Trial name
- NCT04322786
- Testing
- ACE inhibitor
- Volunteers
- 1,302,508 people
- Sponsor
- University College, London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.